619 related articles for article (PubMed ID: 19190520)
1. Cytokeratin expression in malignant melanoma: potential application of in-situ hybridization analysis of mRNA.
Chen N; Gong J; Chen X; Xu M; Huang Y; Wang L; Geng N; Zhou Q
Melanoma Res; 2009 Apr; 19(2):87-93. PubMed ID: 19190520
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
3. Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus, but similarly in primary and metastatic melanomas.
Gong J; Chen N; Zhou Q; Yang B; Wang Y; Wang X
J Clin Pathol; 2005 Oct; 58(10):1081-5. PubMed ID: 16189155
[TBL] [Abstract][Full Text] [Related]
4. The role of RhoC in growth and metastatic capacity of melanoma.
Boone B; Van Gele M; Lambert J; Haspeslagh M; Brochez L
J Cutan Pathol; 2009 Jun; 36(6):629-36. PubMed ID: 19222696
[TBL] [Abstract][Full Text] [Related]
5. In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers.
Bosserhoff AK; Moser M; Hein R; Landthaler M; Buettner R
J Pathol; 1999 Mar; 187(4):446-54. PubMed ID: 10398105
[TBL] [Abstract][Full Text] [Related]
6. Expression of nm23-H1 in uveal melanoma.
Bakalian S; Marshall JC; Faingold D; Logan P; Antecka E; Burnier MN
Melanoma Res; 2007 Oct; 17(5):284-90. PubMed ID: 17885583
[TBL] [Abstract][Full Text] [Related]
7. Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2alpha in cutaneous melanoma.
Karjalainen JM; Kellokoski JK; Mannermaa AJ; Kujala HE; Moisio KI; Mitchell PJ; Eskelinen MJ; Alhava EM; Kosma VM
Br J Cancer; 2000 Jun; 82(12):2015-21. PubMed ID: 10864211
[TBL] [Abstract][Full Text] [Related]
8. Patterns of melastatin mRNA expression in melanocytic tumors.
Deeds J; Cronin F; Duncan LM
Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
[TBL] [Abstract][Full Text] [Related]
9. In situ hybridization and reverse transcription-polymerase chain reaction for cyclin D1 mRNA in the diagnosis of mantle cell lymphoma in paraffin-embedded tissues.
Athanasiou E; Kotoula V; Hytiroglou P; Kouidou S; Kaloutsi V; Papadimitriou CS
Mod Pathol; 2001 Feb; 14(2):62-71. PubMed ID: 11235907
[TBL] [Abstract][Full Text] [Related]
10. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma.
Nürnberg W; Tobias D; Otto F; Henz BM; Schadendorf D
J Pathol; 1999 Dec; 189(4):546-51. PubMed ID: 10629556
[TBL] [Abstract][Full Text] [Related]
11. HER3 is a determinant for poor prognosis in melanoma.
Reschke M; Mihic-Probst D; van der Horst EH; Knyazev P; Wild PJ; Hutterer M; Meyer S; Dummer R; Moch H; Ullrich A
Clin Cancer Res; 2008 Aug; 14(16):5188-97. PubMed ID: 18698037
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.
Vogt T; Stolz W; Welsh J; Jung B; Kerbel RS; Kobayashi H; Landthaler M; McClelland M
Clin Cancer Res; 1998 Mar; 4(3):791-7. PubMed ID: 9533549
[TBL] [Abstract][Full Text] [Related]
13. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
[TBL] [Abstract][Full Text] [Related]
14. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
[TBL] [Abstract][Full Text] [Related]
15. Uveal and cutaneous melanoma: shared expression characteristics of melanoma-associated antigens.
van Dinten LC; Pul N; van Nieuwpoort AF; Out CJ; Jager MJ; van den Elsen PJ
Invest Ophthalmol Vis Sci; 2005 Jan; 46(1):24-30. PubMed ID: 15623750
[TBL] [Abstract][Full Text] [Related]
16. MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma.
Gibbs P; Hutchins AM; Dorian KT; Vaughan HA; Davis ID; Silvapulle M; Cebon JS
Melanoma Res; 2000 Jun; 10(3):259-64. PubMed ID: 10890380
[TBL] [Abstract][Full Text] [Related]
17. Chromogenic in situ hybridization analysis of melastatin mRNA expression in melanomas from American Joint Committee on Cancer stage I and II patients with recurrent melanoma.
Hammock L; Cohen C; Carlson G; Murray D; Ross JS; Sheehan C; Nazir TM; Carlson JA
J Cutan Pathol; 2006 Sep; 33(9):599-607. PubMed ID: 16965333
[TBL] [Abstract][Full Text] [Related]
18. Coexpression of bone sialoprotein (BSP) and the pivotal transcriptional regulator of osteogenesis, Cbfa1/Runx2, in malignant melanoma.
Riminucci M; Corsi A; Peris K; Fisher LW; Chimenti S; Bianco P
Calcif Tissue Int; 2003 Sep; 73(3):281-9. PubMed ID: 14667142
[TBL] [Abstract][Full Text] [Related]
19. Detection of melanoma cells in sentinel lymph nodes by reverse transcriptase-polymerase chain reaction: prognostic significance.
Gradilone A; Ribuffo D; Silvestri I; Cigna E; Gazzaniga P; Nofroni I; Zamolo G; Frati L; Scuderi N; Aglianò AM
Ann Surg Oncol; 2004 Nov; 11(11):983-7. PubMed ID: 15525827
[TBL] [Abstract][Full Text] [Related]
20. Decreased expression of KAI1/CD82 metastasis suppressor gene is associated with loss of heterozygosity in melanoma cell lines.
Kim YI; Shin MK; Lee JW; Chung JH; Lee MH
Oncol Rep; 2009 Jan; 21(1):159-64. PubMed ID: 19082457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
